Astrazeneca News
- All
- News
- Videos
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
-
European Union Drugs Regulator Approves AstraZeneca Jab As Covid Booster
AstraZeneca's Covid jab has won approval for use as a booster or third jab in the European Union, the British drugs giant confirmed Monday.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
Delta Variant Effect: Countries Using AstraZeneca Shots Eyeing Boosters
Growing concern that Covid-19 vaccines being deployed across much of the developing world aren't capable of thwarting the delta variant is prompting some countries to look at offering third doses to bolster immunity.
-
No Ban On Covishield, Request Must For Approval Process: EU Envoy To India
European Union (EU) Ambassador to India Ugo Astuto has clarified there is no ban in the EU on the Covishield vaccine produced by the Serum Institute of India (SII) and developed by AstraZeneca and Oxford University.
-
"Hope To Resolve Soon": Adar Poonawalla On Covishield, EU Travel Issues
Adar Poonawalla tweeted Monday to reassure Covishield-vaccinated Indians facing issues with travel to the European Union - in light of the EU's new 'vaccine passport' scheme not recognising the India-made version of the AstraZeneca vaccine
-
AstraZeneca's Antibody Cocktail Fails to Prevent Covid: Study
AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.
-
Failure of AstraZeneca Trial Big Blow For Anti-Addiction Drugs: Report
The failure of the trial of the drug AZD4041 by pharma giant AstraZeneca, to combat opioid use disorder (OUD), highlights the challenges in developing non-opioid medications that treat addiction and withdrawal, according to a report.
-
Covaxin Has Excellent Safety Record: Bharat Biotech On Study Citing Risks
The study, led by Banaras Hindu University (BHU), claimed that Covaxin raised the rare risk of stroke, and Guillain-Barre syndrome, among others.
-
AstraZeneca Covid Vaccine Linked To Another Fatal Blood Clotting Disorder
AstraZeneca's Covid-19 vaccine, made in collaboration with Oxford University has been found to raise the risk of vaccine-induced immune thrombocytopenia and thrombosis (VITT) -- a rare but fatal blood clotting disorder, claimed researchers today.
-
"We Disclosed All Rare Side-Effects": Covid Vaccine Maker Amid Safety Row
The Serum Institute - which manufactured the Covishield COVID-19 vaccine developed by British pharma giant AstraZeneca - stressed on Wednesday that all its product packaging had "disclosed all rare to very rare side-effects", including TTS.
-
Couple Allege Daughter Died After Taking Covishield, To Sue AstraZeneca
The parents of a young woman who died allegedly after being given Covishield are planning to sue the world's largest vaccine maker and the British pharma giant that had developed the vaccine during the Covid pandemic.
-
AstraZeneca Admits Covishield Jab Has Rare Side-Effect. Should You Worry?
Thrombosis Thrombocytopenia Syndrome (TTS) -- a blood clot disorder -- is a rare side effect of AstraZeneca's Covid vaccine, and the risks far outweigh the benefits of the jab, doctors said today.
-
What Is TTS, A Rare Condition Caused By AstraZeneca's Covishield Vaccine
AstraZeneca, a British pharmaceutical giant, has admitted that its Covid-19 vaccine can result ina rare side effectknown as Thrombosis with Thrombocytopenia Syndrome (TTS).T
-
AstraZeneca Claims Positive Medicine Trial For "Severe" Covid
A treatment for people at risk of death from coronavirus has revealed good results in a late-stage trial, its maker AstraZeneca announced Wednesday.
-
AstraZeneca's Stock Rise 10%, A Day After Dividend Announcement Of Rs 8
AstraZeneca Pharma India Ltd.'s stock jumped nearly 10 per cent, a day after the company's board declared dividend of Rs 8 per share.
-
European Union Drugs Regulator Approves AstraZeneca Jab As Covid Booster
AstraZeneca's Covid jab has won approval for use as a booster or third jab in the European Union, the British drugs giant confirmed Monday.
-
Lancet Study On Covishield Vaccine Protection Decline Is Misquoted: Experts
The Lancet study, which reportedly states that the protection offered by the Oxford AstraZeneca COVID-19 vaccine Covishield declines after 3 months, has been misquoted, said experts.
-
Delta Variant Effect: Countries Using AstraZeneca Shots Eyeing Boosters
Growing concern that Covid-19 vaccines being deployed across much of the developing world aren't capable of thwarting the delta variant is prompting some countries to look at offering third doses to bolster immunity.
-
No Ban On Covishield, Request Must For Approval Process: EU Envoy To India
European Union (EU) Ambassador to India Ugo Astuto has clarified there is no ban in the EU on the Covishield vaccine produced by the Serum Institute of India (SII) and developed by AstraZeneca and Oxford University.
-
"Hope To Resolve Soon": Adar Poonawalla On Covishield, EU Travel Issues
Adar Poonawalla tweeted Monday to reassure Covishield-vaccinated Indians facing issues with travel to the European Union - in light of the EU's new 'vaccine passport' scheme not recognising the India-made version of the AstraZeneca vaccine
-
AstraZeneca's Antibody Cocktail Fails to Prevent Covid: Study
AstraZeneca Plc's antibody cocktail was only 33% effective at preventing COVID-19 symptoms in people who had been exposed to the virus, failing a study that was key to the drugmaker's pandemic push.
